RZLT — Rezolute, Inc.

—
Nasdaq · Health Care · Pharmaceuticals · CIK 1509261 ·
Last close
$4.01
Market Cap
$388.37M
52W High
$11.16
52W Low
$1.07
ADV30
1,679,454
Next earnings
2026-11-05

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGross profitOp incomeNet incomeAssetsCashLiabilities
Sep 2026 0 — -19,385,000 -18,487,000 96,010,000 8,150,000 10,062,000
Jun 2026 0 — -21,562,000 -20,491,000 112,849,000 10,615,000 12,162,000
Mar 2026 0 — -17,366,000 -16,171,000 125,459,000 11,236,000 8,625,000
Dec 2025 0 — -24,221,000 -22,774,000 138,629,000 11,944,000 10,631,000

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$-64,635,000
Investing CF
$-21,098,000
Financing CF
$2,241,000
CapEx
—
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-0.76
As of
2026-11-08

Balance + Analyst (yfinance extras)

Retained Earnings
$-481,442,000
Inventory
—
Receivables
—
ST Investments
$97,186,000
EBIT TTM
$-82,966,000
Pretax Income TTM
$-77,586,000
Interest Exp TTM
—
Analysts
10

Annual Trend (SEC EDGAR, last 4y)

Revenues vs Net Income (last 4y)

FY endRevenuesOp incomeNet incomeAssetsLiabilitiesEquityOp cash flow
Jun 2026 0 -82,966,000 -77,586,000 112,849,000 12,162,000 100,687,000 -64,635,000
Jun 2025 0 -79,894,000 -74,412,000 175,490,000 13,363,000 162,127,000 -69,075,000
Jun 2024 0 -70,423,000 -68,459,000 132,737,000 11,734,000 121,003,000 -57,368,000
Jun 2023 0 -55,990,000 -51,787,000 123,721,000 7,549,000 116,172,000 -44,481,000

TTM Snapshot

Revenues TTM
$0
NetIncome TTM
$-77,586,000
OpCashFlow TTM
—
Assets (Latest)
$125,459,000
Forward EPS
$-0.45

Max Pain — expiry 2027-01-15

max pain strike: $2.50 · spot: $4.25 · call oi: 16,381 · put oi: 1,093
Expected Move to 2027-01-15: ±$1.32 (31.18%) — implied range $2.92 – $5.58 · ATM straddle on $5.00 strike

Peers — same industry

TickerNameMarket CapLastDaily %
IRD Opus Genetics, Inc. $391.45M $4.05 —
ELTP ELITE PHARMACEUTICALS INC /NV/ $397.36M $0.37 —
PTCHF PureTech Health plc $405.77M $1.65 —
CRMD CorMedix Inc. $371.44M $4.67 —
NIKA NIKA PHARMACEUTICALS, INC $369.14M $0.35 —

News headlines (Yahoo Finance, 1h cache)

Rezolute Raises $100 Million, Advances Ersodetug Toward Commercialization
2026-11-13 17:27 · Yahoo
Rezolute Reports Phase 3 upLIFT Study Meets Primary Efficacy Endpoint in Tumor Hyperinsulinism
2026-11-13 15:50 · Yahoo
Rezolute stock rises on positive Phase 3 upLIFT trial results
2026-11-13 14:23 · Yahoo
Rezolute Announces Pricing of Approximately $100 Million Underwritten Offering of Common Stock and Pre-Funded Warrants
2026-11-13 11:19 · Yahoo
Rezolute Reports First Quarter Fiscal 2027 Financial Results and Provides Business Update
2026-11-05 21:05 · Yahoo
Rezolute to Participate in Upcoming Investor Conferences
2026-11-02 12:30 · Yahoo
Rezolute Gets FDA Nod For Pre-BLA Meeting Despite Phase 3 Miss — Retail Expects ‘Huge Rerating’
2026-10-05 12:58 · Yahoo
Rezolute Says FDA Recommends Pre-BLA Meeting for Congenital Hyperinsulinism Treatment
2026-10-05 12:04 · Yahoo
Rezolute Announces FDA Recommendation to Hold a Pre-BLA Meeting as a Precursor to Submitting a Biologics License Application (BLA) for Congenital Hyperinsulinism
2026-10-05 11:00 · Yahoo
Sector Update: Healthcare Stocks Softer Late Afternoon
2026-09-09 19:49 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.